Here Are Some COVID-19 Vaccine Trial Updates
Moderna apply for approval for mRNA vaccine candidate in the US and Europe ( 11/30/2020 )
Today, Moderna announced the completion of their primary efficacy analysis of phase 3 clinical trial. The vaccine candidate is 94.1% effective against COVID-19 and 100% effective against severe COVID-19. In the United States, the company will apply today for emergency use permission.
In addition, conditional marketing authorization would also extend to the European Medicines Agency.
In a press release, Moderna pointed out that 196 individuals enrolled in their 30,000-participant trial now have COVID-19. Of them, 11 belong to the group that had received the vaccine.
There were 30 cases of severe COVID-19, all in the placebo group. In this group, one person died.
The 196 cases of COVID-19 in the study occurred among diverse participants, including older adults and those from minority ethnic groups.
The company stressed that they would submit the results of the study to a peer-reviewed journal. This is the latest COVID-19 Vaccine Trial Updates.
Scientists in the Netherlands plan ‘human challenge’ vaccine study ( 11/26/2020 )
Scientists at the Leiden University Medical Center (LUMC) in the Netherlands hope that SARS-CoV-2 will be intentionally transmitted to participants to test the vaccine efficacy. Already, 240 people have come forward to participate in the “human challenge” trial.
The trial is supported by 1Day Sooner, a non-profit organization advocating for the COVID-19 human challenge trial volunteers. In a press release, they write, “These studies may be essential to development enough proven vaccines to vaccinate the whole world in 2021, not just the wealthy.”
“As Meta Roestenberg, a LUMC researcher who will be involved in the trial, explains: “Such a study can be important in answering questions we still have about COVID-19: How long will you stay protected after an infection? How do we compare vaccines? How many antibodies do you produce? In which cases, how much of the virus load causes an infection? With this study, you can answer such questions.
AstraZeneca’s ‘Oxford’ vaccine 70% effective ( 11/23/2020 )
According to a recent press release, the experimental COVID-19 vaccine developed by AstraZeneca and Oxford University protects just over 70 percent of people from developing COVID-19. While this is lower than the Pfizer and Moderna vaccines, using a different dosing regimen may increase the protection to 90%.
The latest announcement is based on data from 24,000 participants in three countries. Importantly, the Oxford vaccine is more cost-effective to produce and easier to store and transport than the Pfizer and Moderna vaccines.
The so-called Oxford vaccine trial tested two dosing regimens:
- Two full doses, which gave 62 percent protection
- One-half dose followed by a full dose that provided 90% protection
- The director of the Oxford Vaccine Group, Prof. Andrew Pollard, explains:
These results mean that we have an effective vaccine that is going to save many lives. Interestingly, we have found that one of our dosing regimens can be around 90 percent effective, and if this dosing [regime] is used, more people will be vaccinated with the planned supply of the vaccine.
Dr. Stephen Griffin, associate professor at the University of Leeds, U.K., School of Medicine, says:
This is even more fantastic news and can be considered extremely exciting. As for the others we’ve recently heard of the Oxford vaccine is capable of generating 90 percent protection against COVID-19. Given the favorable stability seen for this vaccine, it has great potential to be delivered across the globe, achieving huge public health benefits.
Dr. Griffin was not involved with the study.
Pfizer and BioNTech COVID-19 candidate vaccine is 95% effective ( 11/19/2020 )
Pfizer and BioNTech announced the results from their phase 3 clinical trial in a recent press release. According to the results, the experimental vaccine is 95 percent effective. These results build on preliminary results that were announced last week.
The new press release states that “[e]fficacy was consistent across age, gender, race, and ethnicity demographics” and in people over 65.
The study included 43,000 participants and no significant safety concerns were identified by the scientists. The researchers have dubbed their mRNA vaccine candidate BNT162.
“Companies expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses by the end of 2021, according to the press release.”
Our Social Media Links :
Facebook – https://www.facebook.com/NUTSHELLSCHOOL
Instagram – https://www.instagram.com/nutshell_school/